We are international
Donate
TEXT SIZE   


Phase III THALOMID® Clinical Trials
05.01.08

US TRIALS

  • A Phase III Study for Patients Relapsing or Progressing After Autologous Transplantation on Total Therapy 2 (TT2, UARK 98-026): Bortezomib, Thalidomide and Dexamethasone Versus Bortezomib, Melphalan, and Dexamethasone (2006-05)
    Little Rock, AR

  • A Phase III Randomized Study of Tandem Transplants With or Without Bortezomib (Velcade) and Thalidomide (Thalomid) to Evaluate Its Effect on Response Rate and Durability of Response in Multiple Myeloma Patients (UARK 2006-15)
    Little Rock, AR

  • Tandem Autotransplantation for Multiple Myeloma Patients With Less Than 12 Months of Preceding Therapy, Incorporating Bortezomib With the Transplant Chemotherapy and During Maintenance (25009)
    Salt Lake City, UT

  • A Randomized Phase III Study Of Thalidomide And Prednisone As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients With Multiple Myeloma (ECOG-NCIC-JMY10)
    multicenter

  • A Phase III Randomized Trial of Thalidomide Plus Zoledronic Acid Versus Zoledronic Acid Alone in Patients With Early Stage Multiple Myeloma (MAYO-MC0289)
    multicenter

  • Randomized Phase 3b Study of Three Treatment Regimens in Subjects With Previously Untreated Multiple Myeloma Who Are Not Considered Candidates for High-Dose Chemotherapy and Autologous Stem Cell Transplantation: VELCADE,Thalidomide, and Dexamethasone Versus VELCADE and Dexamethasone Versus VELCADE, Melphalan, and Prednisone (C05009)
    multicenter

  • An Intergroup Phase III Randomized Controlled Trial Comparing Melphalan, Prednisone and Thalidomide (MPT) Versus Melphalan, Prednisone and Lenalidomide (Revlimid™) (MPR) in Newly Diagnosed Multiple Myeloma Patients Who Are Not Candidates for High-Dose Therapy (ECOG-E1A06)
    multicenter

  • A Study of Autologous Transplantation for Patients With Multiple Myeloma Comparing Melphalan 280 mg/m + Amifostine With Melphalan 200mg/m + Amifostine, Followed by Further Dose Intensification and Maintenance Therapy (FHCRC-2004.00)
    multicenter

FOREIGN TRIALS

  • A Randomized Phase III Study Of Thalidomide And Prednisone As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients With Multiple Myeloma (ECOG-NCIC-JMY10)
    Canada - multicenter

  • GEM05 for Patients With Multiple Myeloma Under 65 Years (2005-001110-41)
    Spain - multicenter

  • GEM05 for Patients With Multiple Myeloma More than 65 Years (2005-001111-21)
    Spain - multicenter

  • Thalidomide Versus Bortezomib in Melphalan Refractory Myeloma (NMSG 17/07)
    multicenter

  • A Randomized Controlled Study of Velcade (Bortezomib) Plus Thalidomide Plus Dexamethasone Compared to Thalidomide Plus Dexamethasone for the Treatment of Myeloma Patients Progressing or Relapsing After Autologous Transplantation (EBMT-CLWP: 42206611)
    multicenter


 related articles